WallStreetZenWallStreetZen

NASDAQ: NMRA
Neumora Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NMRA

Based on 6 analysts offering 12 month price targets for Neumora Therapeutics Inc

Min Forecast
$1.00-38.27%
Avg Forecast
$5.83+260.06%
Max Forecast
$18.00+1,011.11%

Should I buy or sell NMRA stock?

Based on 6 analysts offering ratings for Neumora Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
3 analysts 50%
Hold
2 analysts 33.33%
Sell
1 analysts 16.67%
Strong Sell
0 analysts 0%
Although NMRA's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates NMRA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their NMRA stock forecasts and price targets.

NMRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-16
lockedlocked$00.00+00.00%2025-05-13
lockedlocked$00.00+00.00%2025-04-02
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-03-07
RBC Capital
Bottom 6%
6
HoldReiterates$4.00+146.91%2025-03-04

1 of 1

Forecast return on equity

Is NMRA forecast to generate an efficient return?

Company
-77.04%
Industry
123.99%
Market
-49.26%
NMRA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NMRA forecast to generate an efficient return on assets?

Company
-62.95%
Industry
47.19%
NMRA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NMRA earnings per share forecast

What is NMRA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.29
Avg 2 year Forecast
-$1.03
Avg 3 year Forecast
-$0.94

NMRA revenue forecast

What is NMRA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$29.4M
Avg 2 year Forecast
$4.4M
Avg 3 year Forecast
$97.2M

NMRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NMRA$1.62$5.83+260.06%Hold
GALT$4.10$6.00+46.34%Buy
TVRD$28.05$59.20+111.05%Strong Buy
ALLO$1.19$8.44+609.58%Strong Buy
PBYI$5.25$7.00+33.33%Buy
View Top Biotech Stocks

Neumora Therapeutics Stock Forecast FAQ

Is Neumora Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: NMRA) stock is to Hold NMRA stock.

Out of 6 analysts, 0 (0%) are recommending NMRA as a Strong Buy, 3 (50%) are recommending NMRA as a Buy, 2 (33.33%) are recommending NMRA as a Hold, 1 (16.67%) are recommending NMRA as a Sell, and 0 (0%) are recommending NMRA as a Strong Sell.

If you're new to stock investing, here's how to buy Neumora Therapeutics stock.

What is NMRA's earnings growth forecast for 2025-2027?

(NASDAQ: NMRA) Neumora Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.

Neumora Therapeutics's earnings in 2025 is -$252,089,000.On average, 4 Wall Street analysts forecast NMRA's earnings for 2025 to be -$209,314,464, with the lowest NMRA earnings forecast at -$249,395,958, and the highest NMRA earnings forecast at -$139,273,067. On average, 4 Wall Street analysts forecast NMRA's earnings for 2026 to be -$165,994,063, with the lowest NMRA earnings forecast at -$262,351,592, and the highest NMRA earnings forecast at -$58,300,354.

In 2027, NMRA is forecast to generate -$152,763,121 in earnings, with the lowest earnings forecast at -$270,448,863 and the highest earnings forecast at -$40,486,357.

What is NMRA's revenue growth forecast for 2026-2028?

(NASDAQ: NMRA) Neumora Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.

Neumora Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NMRA's revenue for 2026 to be $4,756,337,191, with the lowest NMRA revenue forecast at $4,756,337,191, and the highest NMRA revenue forecast at $4,756,337,191. On average, 2 Wall Street analysts forecast NMRA's revenue for 2027 to be $719,037,696, with the lowest NMRA revenue forecast at $328,749,217, and the highest NMRA revenue forecast at $1,109,326,175.

In 2028, NMRA is forecast to generate $15,744,334,413 in revenue, with the lowest revenue forecast at $15,349,187,571 and the highest revenue forecast at $16,139,481,255.

What is NMRA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NMRA) forecast ROA is -62.95%, which is lower than the forecast US Biotechnology industry average of 47.19%.

What is NMRA's Price Target?

According to 6 Wall Street analysts that have issued a 1 year NMRA price target, the average NMRA price target is $5.83, with the highest NMRA stock price forecast at $18.00 and the lowest NMRA stock price forecast at $1.00.

On average, Wall Street analysts predict that Neumora Therapeutics's share price could reach $5.83 by Jul 16, 2026. The average Neumora Therapeutics stock price prediction forecasts a potential upside of 260.06% from the current NMRA share price of $1.62.

What is NMRA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NMRA) Neumora Therapeutics's current Earnings Per Share (EPS) is -$1.57. On average, analysts forecast that NMRA's EPS will be -$1.29 for 2025, with the lowest EPS forecast at -$1.54, and the highest EPS forecast at -$0.86. On average, analysts forecast that NMRA's EPS will be -$1.03 for 2026, with the lowest EPS forecast at -$1.62, and the highest EPS forecast at -$0.36. In 2027, NMRA's EPS is forecast to hit -$0.94 (min: -$1.67, max: -$0.25).

What is NMRA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NMRA) forecast ROE is -77.04%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.